No Data
No Data
Buy Rating for Pliant Therapeutics Backed by Promising Phase 2a Results of Bexotegrast in IPF Treatment
TD Cowen Sticks to Their Buy Rating for Pliant Therapeutics (PLRX)
Buy Rating Affirmed for Pliant Therapeutics on Promising Bexotegrast Trial Results in IPF
Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX) and Tenet Healthcare (THC)
Sector Update: Health Care Stocks Ease in Tuesday Afternoon Trading
Health care stocks were decreasing Tuesday afternoon, with the NYSE Health Care Index fractionally lower and the Health Care Select Sector SPDR Fund (XLV) down 0.1% The iShares Biotechnology ETF (IBB)
Pliant Therapeutics' Drug Trial Shows Promise In Reversing Lung Fibrosis In Patients
On Tuesday, Pliant Therapeutics Inc (NASDAQ:PLRX) announced topline data from a Phase 2a PET Imaging trial of bexotegrast (PLN-74809) evaluating change in total collagen levels in the lungs of patient